Intra-Cellular Therapies Inc (ITCI):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Intra-Cellular Therapies Inc (ITCI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7989
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:44
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Intra-Cellular Therapies Inc (ITI) is a novel drug manufacturer. The company offers product platform such as ITCI Pipeline that includes lumateperone, ITI-007 platform, PDE inhibitor platform and drug discovery platform. The company’s lead product candidate ITI-007-lumateperone is to treat schizophrenia, behavioural disturbances in dementia, sleep and behavioural disturbances associated with autism spectrum disorder, other mood disorders, sleep disturbances associated with neurologic and psychiatric disorders, and others. Its CNSProfile technology monitors the phosphoprotein changes and generates a unique molecular signature for drug compounds. The company utilizes phosphodiesterase platform and other proprietary chemistry platforms to develop drugs for the treatment of central nervous system and other disorders. ITI is headquartered in New York, the US.

Intra-Cellular Therapies Inc (ITCI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Intra-Cellular Therapies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Intra-Cellular Therapies Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Intra-Cellular Therapies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Intra-Cellular Therapies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Intra-Cellular Therapies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Intra-Cellular Therapies Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Intra-Cellular Therapies Raises US$15 Million In Venture Financing 10
Merger 11
Intra-Cellular Therapies And Public Shell Company Complete Reverse Merger Transaction 11
Licensing Agreements 12
Intra-Cellular Therapies Enters Into Licensing Agreement with ITI 12
Equity Offering 13
Intra-Cellular Therapies Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD172 Million 13
Intra-Cellular Therapies Raises USD345.2 Million in Public Offering of Shares 15
Intra-Cellular Therapies Raises USD130 Million in Public Offering of Shares 17
Intra-Cellular Therapies Completes Public Offering Of Shares For US$123.6 Million 19
Intra-Cellular Therapies Completes Private Placement Of Shares For US$44.7 Million 21
Intra-Cellular Therapies Inc – Key Competitors 23
Intra-Cellular Therapies Inc – Key Employees 24
Intra-Cellular Therapies Inc – Locations And Subsidiaries 25
Head Office 25
Recent Developments 26
Financial Announcements 26
Aug 02, 2018: Intra-Cellular Therapies provides corporate update and reports second quarter 2018 financial results 26
May 03, 2018: Intra-Cellular Therapies Reports First Quarter 2018 Financial Results and Provides Corporate Update 28
Mar 01, 2018: Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update 30
Nov 08, 2017: Intra-Cellular Therapies Reports Third Quarter 2017 Financial Results and Provides Corporate Update 33
Aug 09, 2017: Intra-Cellular Therapies Reports Second Quarter 2017 Financial Results and Provides Corporate Update 35
May 10, 2017: Intra-Cellular Therapies Reports First Quarter 2017 Financial Results and Provides Corporate Update 37
Mar 01, 2017: Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2016 Financial Results and Provides Corporate Update 39
Corporate Communications 41
Oct 16, 2018: Intra-Cellular Therapies appoints Mark Neumann as executive vice president, chief commercial officer 41
Sep 25, 2018: Intra-Cellular Therapies names Michael Olchaskey as Senior Vice President, Head of Regulatory Affairs 42
Nov 13, 2017: Intra-Cellular Therapies Expands Its Executive Team with the Appointment of Dr. Andrew Satlin as Executive Vice President and Chief Medical Officer 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
Intra-Cellular Therapies Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Intra-Cellular Therapies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Intra-Cellular Therapies Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Intra-Cellular Therapies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Intra-Cellular Therapies Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Intra-Cellular Therapies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Intra-Cellular Therapies Raises US$15 Million In Venture Financing 10
Intra-Cellular Therapies And Public Shell Company Complete Reverse Merger Transaction 11
Intra-Cellular Therapies Enters Into Licensing Agreement with ITI 12
Intra-Cellular Therapies Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD172 Million 13
Intra-Cellular Therapies Raises USD345.2 Million in Public Offering of Shares 15
Intra-Cellular Therapies Raises USD130 Million in Public Offering of Shares 17
Intra-Cellular Therapies Completes Public Offering Of Shares For US$123.6 Million 19
Intra-Cellular Therapies Completes Private Placement Of Shares For US$44.7 Million 21
Intra-Cellular Therapies Inc, Key Competitors 23
Intra-Cellular Therapies Inc, Key Employees 24

List of Figures
Intra-Cellular Therapies Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Intra-Cellular Therapies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Intra-Cellular Therapies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Intra-Cellular Therapies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Intra-Cellular Therapies Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Intra-Cellular Therapies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Intra-Cellular Therapies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Intra-Cellular Therapies Inc (ITCI):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Veidekke ASA (VEI):企業の財務・戦略的SWOT分析
    Veidekke ASA (VEI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Plexus Corp (PLXS):企業の財務・戦略的SWOT分析
    Plexus Corp (PLXS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • NVR Inc:戦略・SWOT・企業財務分析
    NVR Inc - Strategy, SWOT and Corporate Finance Report Summary NVR Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • BKW AG:企業の戦略・SWOT・財務分析
    BKW AG - Strategy, SWOT and Corporate Finance Report Summary BKW AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • Trinity Health:企業の戦略・SWOT・財務分析
    Trinity Health - Strategy, SWOT and Corporate Finance Report Summary Trinity Health - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Southwest Gas Corp (SWX):企業の財務・戦略的SWOT分析
    Southwest Gas Corp (SWX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Cytodyn Inc (CYDY):企業の財務・戦略的SWOT分析
    Summary Cytodyn Inc (Cytodyn) is a clinical-stage biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment of Human Immunodeficiency Virus (HIV) infections. Its pipeline products include Leronlimab (PRO 140), a ful …
  • Crane Co.:企業の戦略・SWOT・財務情報
    Crane Co. - Strategy, SWOT and Corporate Finance Report Summary Crane Co. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Oil States International, Inc.:企業の戦略・SWOT・財務情報
    Oil States International, Inc. - Strategy, SWOT and Corporate Finance Report Summary Oil States International, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Vilniaus Degtine AB:戦略・SWOT・企業財務分析
    Vilniaus Degtine AB - Strategy, SWOT and Corporate Finance Report Summary Vilniaus Degtine AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Kawasaki Heavy Industries Ltd (7012):企業の財務・戦略的SWOT分析
    Kawasaki Heavy Industries Ltd (7012) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Ecsponent Limited (ECS):企業の財務・戦略的SWOT分析
    Ecsponent Limited (ECS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • GFI Informatique (GFI):企業の財務・戦略的SWOT分析
    GFI Informatique (GFI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Viacom, Inc.:企業の戦略・SWOT・財務情報
    Viacom, Inc. - Strategy, SWOT and Corporate Finance Report Summary Viacom, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • FibroStatin SL:製薬・医療:M&Aディール及び事業提携情報
    Summary FibroStatin SL (FibroStatin) is a drug development company that focuses on the development of treatment candidates for drug resistant lung cancer and idiopathic pulmonary fibrosis. The company’s pipeline products include T12/FST12 for NSCLC, GPBP-Mab/FSM26 for idiopathic pulmonary fibrosis a …
  • Duke Energy Corp (DUK):企業の財務・戦略的SWOT分析
    Duke Energy Corp (DUK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Odakyu Electric Railway Co., Ltd. (9007):企業の財務・戦略的SWOT分析
    Odakyu Electric Railway Co., Ltd. (9007) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Castle Brands Inc.:企業の戦略・SWOT・財務分析
    Castle Brands Inc. - Strategy, SWOT and Corporate Finance Report Summary Castle Brands Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Close Brothers Group Plc:企業の戦略・SWOT・財務情報
    Close Brothers Group Plc - Strategy, SWOT and Corporate Finance Report Summary Close Brothers Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Grupo Mexico SAB de CV:戦略・SWOT・企業財務分析
    Grupo Mexico SAB de CV - Strategy, SWOT and Corporate Finance Report Summary Grupo Mexico SAB de CV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆